As a urologic oncologist, Dr. Paul L. Crispen specializes in the surgical treatment of cancers involving the kidney, bladder, prostate, testis and penis. His clinical interests focus on the surgical management of renal and bladder cancer, including minimally invasive techniques. While his practice focuses on the surgical management of urologic malignancies, he places great emphasis on multidisciplinary cancer care involving medical and radiation oncologists. Administratively, Dr. Crispen is an active member of the UFHealth Cancer Center and the leader of the Genitourinary Disease Site Group and the chairman of the Scientific Review and Monitoring Committee.
Dr. Crispen also is an associate professor and his research interest is primarily related to improving the evaluation and treatment of patients presenting with genitourinary malignancies. To date, most of his research effort has focused on the management of bladder and kidney cancer. Additionally, he has a strong interest in involving appropriately selected patients in clinical trials which are designed to evaluate new treatment regimens and hopefully improve the care of patients at the University of Florida and beyond.
Areas of Expertise (2)
Media Appearances (1)
Bladder Cancer--Susan's Road to Accpetance
Hope & Healing: The UF Health Blog online
“The best advice for someone diagnosed with bladder cancer is to make sure you know all of your options,” said Crispen. “I encourage patients to ask open questions to their care providers and participate in bladder cancer advocacy groups locally and nationally. Shelly Doran, a genitourinary oncology nurse navigator, has set up a local support group for patients at UF Health. Additionally, the Bladder Cancer Advocacy Network is an excellent organization that provides a wealth of resources to patients. In terms of treatment, I encourage patients to consider clinical trials, which offer our patients the latest breakthroughs in the treatment of bladder cancer.”
Mchanisms of immune evasion in bladder cancerCancer Immunology, Immunotherapy
Paul L. Crispen and Sergei Kusmartsev
With the introduction of multiple new agents, the role of immunotherapy is rapidly expanding across all malignancies. Bladder cancer is known to be immunogenic and is responsive to immunotherapy including intravesical BCG and immune checkpoint inhibitors. Multiple trials have addressed the role of checkpoint inhibitors in advanced bladder cancer, including atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab (all targeting the PD1/PD-L1 pathway). While these trials have demonstrated promising results and improvements over existing therapies, less than half of patients with advanced disease demonstrate clinical benefit from checkpoint inhibitor therapy. Recent breakthroughs in cancer biology and immunology have led to an improved understanding of the influence of the tumor microenvironment on the host’s immune system.